CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 61 enrolled
Drug / intervention
Fesoterodine Fumaratedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01786967
NCT01786967Phase 3Completed
CompareCT.gov

Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly

University of North Carolina, Chapel Hill·interventional·Posted Feb 8, 2013·Updated Mar 18, 2020

In Brief

A Phase 3 clinical trial evaluating Fesoterodine Fumarate for Urge Urinary Incontinence. Completed, enrolled 61 participants across 1 site.

Detailed Summary

Urge urinary incontinence, characterized by unpredictable and embarrassing large volume urine leakage, is a major health issue for elderly women, as it is incredibly common and significantly impairs quality of life. Although anticholinergic medications are the most common therapy, the investigators are unable to predict an individual's response to a particular drug in terms of both effectiveness and side effects. Through genetic evaluation, the investigators have the potential to personalize and optimize drug therapy for millions of elderly women suffering from urge incontinence.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrge Urinary Incontinence
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 8, 2013
Enrollment StartSep 1, 2012
Primary CompletionDec 31, 2017
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 13.4 years ago

Interventions

Fesoterodine Fumaratedrug

FDA approved anticholinergic medication used for treatment of urge urinary incontinence